PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31960422-2 2020 Here we aimed to determine how this different genetic background would affect the interaction between the EGFR-inhibitor erlotinib and the cMET-inhibitor crizotinib. erlotinib 121-130 epidermal growth factor receptor Homo sapiens 106-110 31885349-0 2020 Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. erlotinib 12-21 epidermal growth factor receptor Homo sapiens 48-52 31747091-5 2020 EGFR inhibitors including both monoclonal antibodies (cetuximab and panitumumab) and tyrosine kinase inhibitors (erlotinib, gefitinib and dasatinib) have been used in clinical trials for the treatment of advanced cSCC, achieving only partial clinical benefit. erlotinib 113-122 epidermal growth factor receptor Homo sapiens 0-4 31730733-6 2020 Since an epidermal growth factor receptor mutation was identified by analysis of the exfoliated tumour cells in pleural effusion, erlotinib was administered, without further treatment of the membranous nephropathy. erlotinib 130-139 epidermal growth factor receptor Homo sapiens 9-41 31730733-8 2020 WHAT IS NEW AND CONCLUSION: For patients with EGFR-mutation-positive lung adenocarcinoma associated with paraneoplastic membranous nephropathy, erlotinib might serve as a treatment option for both the tumour and the membranous nephropathy. erlotinib 144-153 epidermal growth factor receptor Homo sapiens 46-50 31954111-7 2020 Our results demonstrate that combination therapy involving ERL and CDODA-Me overcomes resistance through dual inhibition of p-EGFR and p-MET leading to the induction of apoptosis, intracellular ROS accumulation and decreased mitochondrial potential. erlotinib 59-62 epidermal growth factor receptor Homo sapiens 126-130 32070872-0 2020 Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab. erlotinib 185-194 epidermal growth factor receptor Homo sapiens 74-106 31972351-9 2020 In the LMC model with A925L/AR cells, combined treatment with alectinib and EGFR-TKIs, such as erlotinib and osimertinib, successfully controlled progression of LMC. erlotinib 95-104 epidermal growth factor receptor Homo sapiens 76-80 31778239-1 2020 WHAT IS KNOWN AND OBJECTIVE: Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. erlotinib 29-38 epidermal growth factor receptor Homo sapiens 116-148 31778239-1 2020 WHAT IS KNOWN AND OBJECTIVE: Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. erlotinib 29-38 epidermal growth factor receptor Homo sapiens 150-154 31838083-0 2020 Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. erlotinib 135-144 epidermal growth factor receptor Homo sapiens 120-124 31838083-6 2020 Moreover, we discovered that the NGF/TrkA axis conferred resistance to the EGFR inhibitor erlotinib via EMT processes in HNSCC cells. erlotinib 90-99 epidermal growth factor receptor Homo sapiens 75-79 31595681-1 2020 ATP-analogue inhibitors, Gefitinib (Iressa) and Erlotinib (Tarceva), had been approved for advanced and metastatic NSCLC against tyrosine kinase domain of EGFR. erlotinib 48-57 epidermal growth factor receptor Homo sapiens 155-159 31820199-0 2020 Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. erlotinib 11-20 epidermal growth factor receptor Homo sapiens 66-70 31812754-1 2020 BACKGROUND: Longitudinal evaluation of mutations in blood samples was a pre-specified secondary objective in the BELIEF trial of erlotinib/bevacizumab in advanced EGFR-positive NSCLC. erlotinib 129-138 epidermal growth factor receptor Homo sapiens 163-167 31894866-5 2020 The three-dimensional quantitative structure-activity relationships and molecular modeling studies revealed comparable binding modes of compound 6b, gefitinib, and erlotinib in the EGFR active site. erlotinib 164-173 epidermal growth factor receptor Homo sapiens 181-185 32022097-3 2020 Specifically, erlotinib and alpha-tocopheryl succinate (alpha-TOS), which are respectively an epidermal growth factor receptor (EGFR) inhibitor and mitochondria destabilizer, were efficiently loaded into porous and nonporous poly(ester-thioether) microspheres for the treatment of EGFR-overexpressing NSCLC (A549 cells). erlotinib 14-23 epidermal growth factor receptor Homo sapiens 94-126 32022097-3 2020 Specifically, erlotinib and alpha-tocopheryl succinate (alpha-TOS), which are respectively an epidermal growth factor receptor (EGFR) inhibitor and mitochondria destabilizer, were efficiently loaded into porous and nonporous poly(ester-thioether) microspheres for the treatment of EGFR-overexpressing NSCLC (A549 cells). erlotinib 14-23 epidermal growth factor receptor Homo sapiens 128-132 32022097-3 2020 Specifically, erlotinib and alpha-tocopheryl succinate (alpha-TOS), which are respectively an epidermal growth factor receptor (EGFR) inhibitor and mitochondria destabilizer, were efficiently loaded into porous and nonporous poly(ester-thioether) microspheres for the treatment of EGFR-overexpressing NSCLC (A549 cells). erlotinib 14-23 epidermal growth factor receptor Homo sapiens 281-285 31820199-2 2020 OBJECTIVE: We intended to evaluate the combination of pemetrexed/erlotinib in patients with high epidermal growth factor receptor (EGFR)-expressing (2+ or 3 on immunohistochemistry) metastatic CRC who experienced disease progression after standard chemotherapy. erlotinib 65-74 epidermal growth factor receptor Homo sapiens 97-129 31820199-2 2020 OBJECTIVE: We intended to evaluate the combination of pemetrexed/erlotinib in patients with high epidermal growth factor receptor (EGFR)-expressing (2+ or 3 on immunohistochemistry) metastatic CRC who experienced disease progression after standard chemotherapy. erlotinib 65-74 epidermal growth factor receptor Homo sapiens 131-135 31820199-13 2020 CONCLUSION: This phase II trial using pemetrexed/erlotinib in metastatic CRC with high EGFR expression met the primary endpoint of tumor response. erlotinib 49-58 epidermal growth factor receptor Homo sapiens 87-91 32021306-0 2020 Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases. erlotinib 92-101 epidermal growth factor receptor Homo sapiens 22-54 32005679-5 2020 The EGFR inhibitor erlotinib decreased CD4+ effector regulatory T cells infiltration in the TME and in combination with anti-PD-1 mAb showed better antitumor effects than either treatment alone. erlotinib 19-28 epidermal growth factor receptor Homo sapiens 4-8 31969600-9 2020 Co-treatment of cells with pitavastatin and the EGFR TKI erlotinib resulted in synergistically enhanced cytotoxicity compared to pitavastatin monotherapy. erlotinib 57-66 epidermal growth factor receptor Homo sapiens 48-52 32038917-0 2019 Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer. erlotinib 0-9 epidermal growth factor receptor Homo sapiens 54-58 31827134-2 2019 Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a therapeutic challenge. erlotinib 90-99 epidermal growth factor receptor Homo sapiens 72-76 31691527-12 2019 In addition, erlotinib, a US Food and Drug Administration approved cancer drug which targets EGFR, was able to rescue MYST1-promoted cell proliferation and EGFR signaling pathway. erlotinib 13-22 epidermal growth factor receptor Homo sapiens 156-160 31591063-18 2019 INTERPRETATION: Ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. erlotinib 33-42 epidermal growth factor receptor Homo sapiens 155-159 31936715-4 2020 Moreover, blockade of HB-EGF-EGFR signaling, by an anti-HB-EGF neutralizing antibody or the EGFR inhibitor erlotinib, limited the angiogenic potential of bone marrow endothelial cells and hampered tumor growth in an MM xenograft mouse model. erlotinib 107-116 epidermal growth factor receptor Homo sapiens 29-33 31559898-1 2020 EGFR-TKIs such as erlotinib and gefitinib have been introduced into the first-line treatment for patients having a mutation of deletion in exon 19 or L858R missense mutations in exon 21. erlotinib 18-27 epidermal growth factor receptor Homo sapiens 0-4 31938054-6 2020 Its down-regulation leads to constitutive activation of EGFR, an observation which prompted us to test the effect of the EGFR inhibitor erlotinib/Tarceva (ERLO) in addition to BVZ/IFN. erlotinib 136-145 epidermal growth factor receptor Homo sapiens 121-125 31843782-1 2019 Erlotinib used in the treatment of advanced non-small cell lung cancer (NSCLC) is a first-generation small-molecule tyrosine kinase inhibitor which reversibly inhibits the kinase domain of epithelial growth factor receptor (EGFR). erlotinib 0-9 epidermal growth factor receptor Homo sapiens 189-222 31843782-1 2019 Erlotinib used in the treatment of advanced non-small cell lung cancer (NSCLC) is a first-generation small-molecule tyrosine kinase inhibitor which reversibly inhibits the kinase domain of epithelial growth factor receptor (EGFR). erlotinib 0-9 epidermal growth factor receptor Homo sapiens 224-228 32016064-0 2019 Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? erlotinib 0-9 epidermal growth factor receptor Homo sapiens 31-35 31691527-12 2019 In addition, erlotinib, a US Food and Drug Administration approved cancer drug which targets EGFR, was able to rescue MYST1-promoted cell proliferation and EGFR signaling pathway. erlotinib 13-22 epidermal growth factor receptor Homo sapiens 93-97 31772161-0 2019 Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRbeta-IL-6 axis in MUC1-positive cervical cancer. erlotinib 0-9 epidermal growth factor receptor Homo sapiens 75-79 31772161-4 2019 Erlotinib, an EGFR-TKI, effectively impedes CSCs enrichment in paclitaxel-resistant cells through inhibiting IL-6. erlotinib 0-9 epidermal growth factor receptor Homo sapiens 14-18 31772161-9 2019 Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer. erlotinib 178-187 epidermal growth factor receptor Homo sapiens 54-58 31762748-0 2019 The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. erlotinib 58-67 epidermal growth factor receptor Homo sapiens 18-22 31740864-0 2019 Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung. erlotinib 46-55 epidermal growth factor receptor Homo sapiens 107-139 31740864-0 2019 Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung. erlotinib 80-89 epidermal growth factor receptor Homo sapiens 107-139 31740864-1 2019 Objective: To assess the efficacy and tolerability of erlotinib in combination with radiation therapy followed by maintenance therapy in Stage III and IV, epidermal growth factor receptor mutationpositive adenocarcinoma lung patients. erlotinib 54-63 epidermal growth factor receptor Homo sapiens 155-187 31740864-14 2019 CONCLUSIONS: Concurrent radiotherapy with erlotinib was effective and well-tolerated in patients with locally advanced adenocarcinoma lung harbouring epidermal growth factor receptor mutation. erlotinib 42-51 epidermal growth factor receptor Homo sapiens 150-182 31803256-2 2019 Acquired resistance inevitably develops, with the EGFR T790M mutation comprising approximately 55% of the mechanisms of resistance following first- or second-generation EGFR-TKI therapy (e.g. gefitinib, erlotinib, afatinib, and dacomitinib). erlotinib 203-212 epidermal growth factor receptor Homo sapiens 50-54 31857948-2 2019 Gefitinib and erlotinib were the first two reversible inhibitors of the EGFR kinase. erlotinib 14-23 epidermal growth factor receptor Homo sapiens 72-76 31671561-3 2019 Gefitinib, erlotinib, afatinib, and osimertinib are TK inhibitors (TKIs) that specifically target EGFR and are currently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first line treatment for sensitive EGFR-mutant patients. erlotinib 11-20 epidermal growth factor receptor Homo sapiens 98-102 31695757-1 2019 Background: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as erlotinib is a major challenge to achieve an overall clinical benefit of the targeted therapy. erlotinib 117-126 epidermal growth factor receptor Homo sapiens 35-67 31695757-1 2019 Background: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as erlotinib is a major challenge to achieve an overall clinical benefit of the targeted therapy. erlotinib 117-126 epidermal growth factor receptor Homo sapiens 69-73 31554377-0 2019 Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib. erlotinib 107-116 epidermal growth factor receptor Homo sapiens 10-42 31567201-0 2021 Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer. erlotinib 39-48 epidermal growth factor receptor Homo sapiens 72-76 31567201-2 2021 Erlotinib is a reversible epidermal growth factor receptor (EGFR) inhibitor, which was approved at its maximum tolerated dose of 150 mg/d determined from the initial phase I study. erlotinib 0-9 epidermal growth factor receptor Homo sapiens 26-58 31567201-2 2021 Erlotinib is a reversible epidermal growth factor receptor (EGFR) inhibitor, which was approved at its maximum tolerated dose of 150 mg/d determined from the initial phase I study. erlotinib 0-9 epidermal growth factor receptor Homo sapiens 60-64 31554377-1 2019 BACKGROUND: Despite effective activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib, all non-small cell lung cancer (NSCLC) patients eventually acquire resistance to these agents. erlotinib 125-134 epidermal growth factor receptor Homo sapiens 76-80 31698647-3 2019 Erlotinib, an EGFR tyrosine kinase inhibitor, was recommended as the second-line therapy for pre-treated patients. erlotinib 0-9 epidermal growth factor receptor Homo sapiens 14-18 31555526-3 2019 A Chinese Han male patient (64 years old) who was initially diagnosed with EGFR-19-deletion-positive advanced NSCLC had a satisfactory clinical response after treatment with erlotinib. erlotinib 174-183 epidermal growth factor receptor Homo sapiens 75-79 31571631-2 2019 Erlotinib and gefitinib are the first-generation EGFR-TKIs for patients with NSCLC. erlotinib 0-9 epidermal growth factor receptor Homo sapiens 49-53